

LOBULAR BREAST CANCER UK

England & Wales · Charity number 1191402

Details

Status Registered

Legal form CIO

Registered 2020-09-22

Register [View on the Charity Commission register](#)

Contact

Address Acorn Business Centre
Unit C
Aldow Enterprise Park
Blackett Street
Manchester
M12 6AE

Phone 07879426491

Email info@lobularbreastcancer.org.uk

Website www.lobularbreastcancer.org.uk

Activities

Objects: THE OBJECT OF THE CIO IS TO PRESERVE AND PROTECT THE HEALTH AND WELLBEING OF PEOPLE IN THE UK THROUGH THE PROVISION OF EDUCATION, TRAINING, SUPPORT WITH TRIALS AND RESEARCH, LOBBYING AND ADVOCACY AROUND LOBULAR BREAST CANCER.

Activities: At Lobular Breast Cancer UK (LBCUK) our charitable object is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around Lobular Breast Cancer.

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Other Charitable Activities
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£14,684	£20,465	-	-
2023-12-31	£24,592	£9,950	-	-
2022-12-31	£29,903	£9,436	-	-
2021-12-31	£4,998	£2,650	-	-

Trustees

Name	Role	Appointed
Anne M Carey	Chair	2024-02-05
Andrea Lener		2025-08-21
Dr Jane Patricia Sedcole		2024-02-05
Elaine Nangle		2022-01-01
Emma Amos		2021-08-15
Hannah Jane Phillips		2024-02-05
Lesley Jane Goodburn		2025-08-21
Professor Sara Jane MacLennan		2024-02-05
Susan Helen Barton		2025-08-21

LOBULAR BREAST CANCER UK

England & Wales - Charity number 1191402

Accounts

LOBULAR BREAST CANCER UK

(A Charitable Incorporated Organisation)

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

**Working together,
we can all live well**

www.lobularbreastcancer.org.uk



LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

Contents

Reference and Administrative Details	1-2
Chair's Statement	3
Trustees Report	4-15
Chartered Accountants' report	16
Statement of financial activities	17
Balance sheet	18
Notes to the Financial Statements	19 - 24

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2024

Registered Charity Name:

Lobular Breast Cancer UK

Charity Registration:

22 September 2020

**Charitable Incorporated Organisation
Registration No:**

CE023524

Charity Registration No:

1191402

The Charity is incorporated in England and Wales

Registered Office

Picadilly Business Centre
Unit C Aldow Enterprise Park
Manchester M12 6AE

Trustees

Emma Amos (Co-Chair 27 October 2024)
Anne M Carey (joined 5 February 2024 Co-Chair 27 October 2024)
Helen Coulthard (retired 5 February 2024)
Professor Sara Jane MacLennan (joined 5 February 2024)
Elaine Nangle
Hannah Jane Phillips (joined 5 February 2024)
Dr Jane Patricia Sedcole (joined 5 February 2024)
Claire Turner (Chair) (retired 27 October 2024)

Patrons

Josie Lloyd
Dame Martina Milburn DCVO CBE

Scientific & Medical Advisory Group (SMAG)

- Professor Val Brunton (University of Edinburgh)
- Dr Soujanya Gadde Consultant Radiologist (The Nightingale Centre Wythenshawe Hospital, Manchester)
- Charlotte Milns Senior Breast Care Nurse (The Nightingale Centre, Wythenshawe Hospital, Manchester)
- Dr Sankari Nagarajan (The University of Manchester)
- Dr Alicia Okines, Medical Oncologist (Royal Marsden Hospital, London)
- Professor Elinor Sawyer, Professor of Clinical Oncology and Breast Cancer Genetics (King's College London & Guys & St Thomas Foundation Trust)

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2024

Accountant

Menzies LLP
One Express
1 George Leigh Street
Manchester
M4 5DL

Bankers

The Co-operative Bank
P.O. Box 250
Delf House
Southway
Skelmersdale
WN8 6WT

Email:

info@lobularbreastcancer.org.uk

Website:

lobularbreastcancer.org.uk

Social Media:

@LobularBCUK

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Chair's Statement
FOR THE YEAR ENDED 31 DECEMBER 2024

2024 has been a transformative and busy year for Lobular Breast Cancer UK.

In our commitment to ensuring that we provide accurate and evidence-based information, support and research for everyone impacted by a Lobular Breast Cancer diagnosis, we conducted the first ever UK Lobular Breast Cancer Patient Survey. 644 women from across the UK completed the survey providing fresh information about their experiences which we presented as a paper at the International ILC Symposium. We aim to build on this new understanding throughout 2025 with further in-depth research into the findings.

Demand for our services and reliable, trusted information and support about Lobular continue to grow. We provide direct services to patients and their families through email and social media communications, our website and online resources and patient meet ups, both in person and digitally.

Collaboration and co-creation remain at the heart of our work and we have strengthened partnerships with key organisations including Breast Cancer Now, De Montfort University, the European Lobular Breast Cancer Advocates and European Lobular Breast Cancer Consortium, Future Dreams, Lobular Breast Cancer Alliance, Lobular Ireland and collaborations with clinicians and researchers across the UK and globally on much needed research into this distinct disease.

We continue to co-ordinate the UK Lobular Breast Cancer Network to increase collaborative working, knowledge sharing and research across the UK.

Our focus on income generation has reduced this year as we were conscious that we were building up inappropriate reserves for our level of turnover. Whilst we have continued to raise funds, we haven't organised any official LBCUK fundraising events this year to bring our reserves in line with our Reserves Policy.

Our Board joins me in thanking our Patrons Josie Lloyd and Dame Martina Milburn; our Scientific and Medical Advisory Group; BBC News' Jane Hill for participating in our films; our families, friends, supporters, partners and anyone who has raised funds for our work.

I want to personally thank our Trustees Emma Amos, Anne Carey, Professor Sara MacLennan, Elaine Nangle, Hannah Philips, Dr Jane Sedcole and our Founder members Dr Helen Coulthard Darlaine Honey, Lorna McHattie, and Ruth Warden for their continued commitment, energy and passion for developing our charity, whilst also living with a Lobular Breast Cancer diagnosis.

2025 will be a year of change for us at LBCUK as we begin work to make real clinical changes as we start our Treatment Guidelines campaign to improve outcomes for patients.

Finally we want to remember everyone who has died this year of Lobular Breast Cancer. One person is too many. Our thoughts and love extend to their families and friends. We commit to working together to ensure that in the future, everyone with a Lobular diagnosis lives and lives well.

Thank you

Claire Turner, Retiring Chair

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees have pleasure in presenting their report and the financial statements of the Charity for the year ended 31 December 2024.

LBCUK's CHARITABLE OBJECTS

The object of the CIO is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around Lobular Breast Cancer.

LOBULAR BREAST CANCER UK

Lobular Breast Cancer UK (LBCUK) is a patient-led voluntary charity registered as a Charitable Incorporated Organisation on 22 September 2020 and launched on 22 September 2021.

We established in response to a lack of information and appropriate treatments for patients diagnosed with Lobular Breast Cancer.

Lobular Breast Cancer is a sub-type of breast cancer that makes up 15% of all breast cancers diagnosed and is the second most common form of the disease.

The key challenges we face include:

- Lobular is a distinct disease that behaves differently from other breast cancers. However current UK guidelines, and many clinicians, do not recognise it as a distinct disease;
- Lobular tumours grow like a spider's web in straight lines rarely forming a lump. This can make it hard to see on scans. As a result, we are often diagnosed at a more advanced stage of the disease and with larger tumours;
- a lack of understanding how Lobular grows, spreads, and responds to treatment. It is an under-researched and under-funded disease;
- ensuring that everyone is told that they have Lobular Breast Cancer, not simply breast cancer. It is impossible to make the best treatment decisions if you do not know that you have Lobular;
- there are no treatments specifically targeted for Lobular;
- more research is needed into the psychological impacts of a Lobular diagnosis.

We are led by people with a lived experience of Lobular Breast Cancer. This ensures that patient needs always remain at the forefront of our work.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

OUR PURPOSE

Working together, we can all live well.

OUR VISION

Lobular Breast Cancer is understood comprehensively, diagnosed effectively, treated appropriately, and patients have access to support across the UK.

OUR VALUES


- The patient is always first.
- We are bold and courageous in speaking up for ourselves and anyone affected by Lobular Breast Cancer.
- We commit to reducing the isolation and fear of a Lobular Breast Cancer diagnosis.
- We are evidence based in all our communications and information.
- We act compassionately towards everyone, recognising and accepting our different experiences and beliefs, and treating each other with care, consideration and respect.
- We are stronger together, collaborating and sharing learning with all our stakeholders.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

HOW WE DELIVERED PUBLIC BENEFIT IN 2024

644

UK women with a Lobular Breast Cancer diagnosis responded to our survey.



21,000


individuals visited the website looking for Lobular information & support




Over

550%

average increase in people reached through our social media



Our first Lobular Patient UK Survey demonstrates differences in monitoring Lobular Breast Cancer across the UK.



1,200

downloads of information from our website



"The first time I'd ever met anyone with a Lobular diagnosis...so good to be able to share as it can feel incredibly lonely."

Participant at our Lobular Meet Up

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

INFORMATION and KNOWLEDGE

During 2024 we experienced an **unprecedented increase in the demand for evidence-based and trusted information and materials about Lobular Breast Cancer** from Lobular patients and the general public through direct email contact, our social media networks and people visiting the website.

In addition to increasing knowledge and understanding for people directly impacted by a Lobular diagnosis, we advanced knowledge and understanding of Lobular, especially the patient experience, with clinicians, health professionals, researchers, relevant charities and the media.

"Excellent update. I regularly refer patients to Lobular Breast Cancer UK. Obtained a wider knowledge about ongoing research."

"I learnt a lot about Lobular cancer still being new to my breast CNS role. I...know the information gained will help me provide better information and support to my patients."

Attendees at webinar for Health Care Professionals in partnership with Breast Cancer Now

During 2024:

- we delivered a new webinar in partnership with Breast Cancer Now for UK Health Care Professionals This is part of their Continuing Professional Development webinar series;
- we co-created with patients and researchers at De Montfort University a series of downloadable digital cards that provide information to help individuals have better, more informed conversations with their medical team at different stages of diagnosis and treatment;



- with a renewed focus to build our media profile we appeared in a range of national media including a front cover and double page spread in the *Mail on Sunday* Health Pages and journalist Victoria Derbyshire's podcast "...and then came Breast Cancer";
- we continued our #22ADayUK campaign to raise understanding about the disease and the number of people diagnosed with Lobular Breast Cancer every day in the UK.

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2024

PATIENT SUPPORT

As a charity, we want to avoid duplication of existing services and recognise that we do not have the capacity or training to provide individual and focused support for Lobular patients. Our strategy focuses on ensuring professional breast cancer support services are up to date with the latest Lobular information and research, and their services can respond to the specific needs of Lobular patients.

In partnership with Future Dreams House, London we developed a series of in-person and online patient meetups enabling over **108 women with a Lobular Breast Cancer diagnosis to connect, share experiences and learn more** about Lobular Breast Cancer.



Our monitoring MRI template letter continues to be downloaded from our website with **over 1,200 women accessing it during 2024**. The letter has been successful in enabling women to access supplementary imaging to monitor their breasts following their initial treatment for a primary Lobular Breast Cancer. It demonstrates patient concerns about the geographical disparities in monitoring evidenced in our UK Patient Survey.

In addition, we continue to respond to hundreds of questions and concerns from the public through our email, social media and direct mail. We work to ensure that anyone with a Lobular diagnosis receives evidence-based information about Lobular Breast Cancer and can also be directed to the most appropriate form of professional support.

POLICY & TREATMENT GUIDELINES

During 2024 we conducted the first ever UK patient survey on the experiences of women across the UK who have had a Lobular Breast Cancer diagnosis. **644 women responded to the survey** and the data was presented as a poster at the International ILC Symposium in Leuven.



The findings demonstrate **clear geographical disparities in how women are treated across the UK**, especially with regards to monitoring post initial treatment.

This information has been built into our Treatment Guidelines campaign to change the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Network (SIGN) guidelines. NICE and SIGN guidelines determine how Lobular patients are treated in our hospitals.

Despite the latest research indicating that Lobular is a distinct sub-type of breast cancer which presents, grows and responds differently to

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2024

some treatments, this is not reflected in the guidelines for treating Lobular across the UK. (Oesterreich et al. 2022)¹.

In addition, to raising the profile of Lobular in health policy decision making we contributed to the following bodies and activities:

- a debate at Westminster Hall on Lobular Breast Cancer;
- as a member of *NICE's Voluntary & Community Forum*;
- our Chair is a member of the National Audit of Primary Breast Cancer.

RESEARCH

We developed new and enhanced our on-going relationships with the leading Lobular clinicians and researchers across the UK and internationally.

We launched and co-ordinate the first **Lobular Breast Cancer UK Network** to build collaboration and relationships between researchers, health professionals and patient advocates from across the UK. By bringing together a diverse range of individuals we plan to action real change in knowledge, understanding and treatment of Lobular across the four countries of the UK.



Our Chair continued her roles as UK Patient Advocate with the European Lobular Breast Cancer Consortium (ELBCC), the European Lobular Breast Cancer Advocates and

GlobMob, the international Lobular advocate group. She now also sits as a member of NICE's Voluntary & Community Forum.

A collaborative study in partnership with De Montfort University, *Missed Cancers: Lobular Breast Cancer that has been missed on screening*, was presented as a poster at the annual International Invasive Lobular Carcinoma (ILC) Symposium in Pittsburgh during September. In addition,

- we were involved as research advocates in a successful application with Guy's Hospital and King's College London for a £250,000 grant from Breast Cancer Now: *Personalised Therapies for Relapsed Lobular Breast Cancer Patients*²;
- we worked with the Royal Marsden to ensure that eligible Lobular patients know about the opportunity to participate in the TRAK-ER liquid biopsy trial

¹ Oesterreich, S. et al. *Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer*. Journal of the National Cancer Institute (2022) <https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac157/6758318?login=false>

² <https://breastcancer.org/breast-cancer-research/our-research-projects/personalised-therapies-relapsed-lobular-breast-cancer-patients>

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2024

- we attended a London meeting of the European Lobular Breast Cancer Consortium's Clinical Studies Working Group to share the latest research and knowledge in Lobular clinical challenges and understanding.
- our Chair was Co-author on a poster with the European Lobular Breast Cancer Advocates presented at San Antonio Breast Cancer Symposium *Enhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer. Unique Challenges across European Countries.*

International ILC Symposium

We took an active and leading role at the International Invasive Lobular Carcinoma (ILC) Symposium in Leuven in September 2024. Our Chair was funded as part of the organising committee. As part of our commitment to drive an increase in funding and delivery of Lobular research, we need to build the patient voice and grow the number of Research Advocates.

For the first time we were able to support two grants for new patients interested in Research Advocacy, one who we continue to work with as part of the charity. In addition, we funded the attendance of four of our Trustee and one of our Co-leads for Research. Volunteer Dr Helen Coulthard, Trustee Professor Sara MacLennan and Chair Claire Turner, developed and led a session on the psychosocial and lifestyle impacts of a Lobular Breast Cancer diagnosis.



LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

INCOME GENERATION

During 2024 we didn't deliver any official LBCUK fundraising events in recognition of our need to spend our reserves on achieving public benefit, rather than building them to inappropriate levels.

Individuals and groups impacted by Lobular Breast Cancer continued to support our work and we want to extend a huge thank you to everyone who has raised funds for us throughout the year. Every invaluable penny raised is spent on the delivery of our work and enables to continue to improve information, knowledge and research for everyone diagnosed with Lobular Breast Cancer.

We have developed a plan to diversify our income streams into more grants, community fundraising, partnerships and research advocacy fees to meet our planned increased expenditure to meet the growing demand for services.

FINANCIAL REVIEW

As a volunteer run charity, we currently have few overheads.

Our annual budgets are approved and monitored by the Board at each meeting. Any variances from the proposed budget are highlighted and discussed at the meetings.

In the opinions of the Trustees, the Charitable Company's assets are sufficient to fulfil the obligations of the Charity.

RESERVES POLICY

Our Reserves Policy aims for a target of between three – six months operational expenditure.

We will maintain our unrestricted reserves at a level which is at equivalent to between three - six months' operational expenditure with a target of £10,000 due to trialling the much-needed appointment of a new Interim-CEO and freelance social media support to meet the increasing and ever-growing demand for our services.

At the balance sheet date the charity held total funds of £31,676 (2023: £37,457) of which £0 (2023: £5,847) were held in restricted funds leaving £31,676 (2023: £31,610) in free reserves.

Due to the success of funding over previous years and currently limited overheads, we have focused on 2024 as a year to implement and utilise our financial resource to enhance the public benefit that we offer as an organisation, rather than focus on a further fundraising drive.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

REVIEW OF RISKS

The Trustees have considered the major risks facing the charity and have put in place appropriate policies and procedures to mitigate them.

Our primary risk is the growing demand for our services and the lack of personnel resource to meet this demand. A Trustee recruitment process will take place in early 2025 to fill identified gaps on the Board. We are working towards an optimum Board of 10 – 12 Trustees.

We have begun testing the appointment of an Interim-CEO for the charity starting from 1 December 2024 for an initial 12 months and working with a freelance digital communications specialist two days a month.

FUTURE PLANS

AIM 1: INFORMATION & KNOWLEDGE: we advance education and understanding of Lobular Breast Cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

AIM 2: SUPPORT: we provide routes to appropriate support and connection for patients, reducing the isolation and fear of a Lobular Breast Cancer diagnosis.

AIM 3: RESEARCH: we work with patients, clinicians and health professionals to ensure that research and trials conducted for Lobular Breast Cancer meet the needs of patients.

AIM 4: POLICY & TREATMENT GUIDELINES: we will work with partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries.

AIM 5: OUR IMPACT: we continue to build LBCUK as an effective, professional and sustainable independent charity, increasing our impact.

A key focus for 2025 is the delivery of our campaign to gain recognition of Lobular Breast Cancer as a distinct disease in the UK Breast Cancer Treatment Guidelines.

We will continue to build stronger collaborative relationships across the UK and internationally with other Lobular specific and breast cancer charities, especially developing the collaborative relationship we have with Breast Cancer Now.

Ensuring the necessary support is in place for Lobular patients is key for 2025. We will be building on our work with Future Dreams House to establish regular in person and online meet up workshops for people to come together, especially in areas facing greater health inequalities.

The development of more research into this distinct disease is essential. We will deliver further Lobular Research Partnership Days to drive forward interest in Lobular research with Early Career Researchers and to develop more individuals who can ensure that the patient voice is included in research.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

STRUCTURE GOVERNANCE & MANAGEMENT

GOVERNING DOCUMENT

The Charity is a Charitable Incorporated Organisation and is governed by its Foundation CIO Constitution. It is registered as a CIO with the Charity Commission for England & Wales.

TRUSTEE INDUCTION, RECRUITMENT & TRAINING

The Trustees are collectively known as the Board.

Trustees are appointed by invitation from the existing Trustees and through an open recruitment process, following a majority vote of the Trustees of the Charity.

Invited potential Trustees are requested to complete a formal application process for open recruitment. All Trustees are interviewed by a panel of at least two Trustees and a recommendation is made to the Board if they are determined to be suitable to be invited as a Trustee.

New Trustees are provided with a copy of the Charity Commission's leaflet for new Trustees, 'The Essential Trustee: what you need to know, what you need to do' (CC3), a copy of our Constitution, a copy of the Charity Governance Code, recent Board minutes and latest Annual Report and Accounts. They also receive a briefing and annual reviews with the current Co-Chairs.

ORGANISATION

The Charity is governed by the Board and managed by the charity's Trustees and four voluntary Founders. The Trustees who have acted during the year are listed above. Four of the listed Trustees are also Founders of the charity.

Trustees meet approximately 4 - 5 times a year to discuss and agree on matters of charity governance, policy and strategy. Further ad hoc meetings are organised as required to address specific issues. Trustees develop strategies to increase charity awareness, widen reach across our stakeholders and build the sustainability of this new and growing organisation.

These meetings also include budget reports and cash flow. Any changes in strategy are discussed, amended and when agreed, adopted as written charity policy by Trustees.

Where risks are identified, steps are taken to mitigate these risks, including reference to how the charity has met its charitable aims in the advancement of education, training, support, research and advocacy. Any actions taken are then reported on and reviewed at subsequent meetings.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2024

The implementation of policies and strategies is delivered operationally by the Trustees and the four volunteer Founder Members. To ensure that our activities are evidence based and reflect the latest scientific knowledge about Lobular Breast Cancer, we have a Scientific and Medical Advisory Group involving six respected clinicians and researchers in the field of Lobular Breast Cancer.

We have no premises and are operate across the UK.

All Trustees and relevant volunteers are DBS checked and participate in relevant training programmes.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Responsibilities of the Trustees
FOR THE YEAR ENDED 31 DECEMBER 2024

RESPONSIBILITIES OF THE TRUSTEES

Under charity law, the Trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the CIO constitution. It is also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity and signed on its behalf by



Emma Amos
Co-Chair of Trustees
29 October 2025

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Chartered Accountants Report to the trustees
FOR THE YEAR ENDED 31 DECEMBER 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Lobular Breast Cancer UK for the year ended 31 December 2024 as set out on pages 16 to 23 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW) we are subject to its ethical and other professional requirements which are detailed at <http://www.icaew.com/en/members/regulations-standards-and-guidance/>.

This report is made solely to the board of directors of Lobular Breast Cancer UK, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Lobular Breast Cancer UK and state those matters that we have agreed to state to the board of directors of Lobular Breast Cancer UK, as a body, in this report, in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Lobular Breast Cancer UK and its board of directors as a body for our work or for this report.

It is your duty to ensure that Lobular Breast Cancer UK has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and of Lobular Breast Cancer UK. You consider that Lobular Breast Cancer UK is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Lobular Breast Cancer UK. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts

Menzies LLP

Menzies LLP
One Express
1 George Leigh Street
Manchester
M4 5DL

Date: 29 October 2025

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Statement of Financial Activities
(Including Income and Expenditure Account and Statement of Total
Recognised Gains and Losses)
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	Unrestricted funds £	Restricted funds £	Total 31 December 2024 £
Income and Endowments from:				
Donations and legacies	2	14,684	-	14684
Other trading activities	3		-	
Total income		14,684	-	14,684
Expenditure on:				
Raising funds	4	(1,572)	-	(1,572)
Charitable activities	5	(13,046)	(5,847)	(18,893)
Total expenditure		(14,618)	(5,847)	(20,465)
Net income / (expenditure)		66	(5,847)	(5,781)
Net movement in funds		66	(5,847)	(5,781)
Reconciliation of funds				
Total funds brought forward		31,610	5,847	37,457
Total funds carried forward	11	31,676		31,676
	Note	Unrestricted funds £	Restricted funds £	Total 2023 £
Income and Endowments from:				
Donations and legacies	2	24,283		24,283
Other trading activities		309		309
Total income		24,592		24,592
Expenditure on:				
Raising funds	4	(1,240)	-	(1,240)
Charitable activities	5	(6,293)	(2,417)	(8,710)
Total expenditure		(7,533)	(2,417)	(9,950)
Net income		17,059	(2,417)	14,642
Net movement in funds		17,059	(2,417)	14,642
Reconciliation of funds				
Total funds brought forward		14,551	8,264	22,815
Total funds carried forward	11	31,610	5,847	37,457

All of the Charity's activities derive from continuing operations during the above two periods.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
(Registration number: CE023524)
Balance Sheet
AS AT 31 DECEMBER 2024

	Note	31 December 2024 £	31 December 2023 £
Current assets			
Cash at bank and in hand		32,426	38,207
Creditors: Amounts falling due within one year	10	(750)	(750)
Net assets		31,676	37,457
Funds of the Charity:			
Restricted funds			5,847
Unrestricted income funds			
Unrestricted funds		31,676	31,610
Total funds	11	31,676	37,457

The financial statements on pages 16 - 23 were approved by the trustees, and authorised for issue on 29 October 2025 and signed on their behalf by:



Emma Amos
Trustee

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Charity status

The Charity is a Charitable Incorporated Organisation, incorporated in England and Wales.

The address of its registered office is:

Piccadilly Business Centre
Unit C Aldow Enterprise Park
Manchester M12 6AE

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") the Charities Act 2011, and Charities (Accounts and Reports) Regulations 2008, as well as the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" 2019.

Basis of preparation

Lobular Breast Cancer UK meets the definition of a public benefit entity under FRS 102. The accounts (financial statements) have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the Charity.

Exemption from preparing a cash flow statement

The Charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the Charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the Charity before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that these conditions will be fulfilled in the reporting period.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

Grants receivable

Grants are recognised when the Charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the Charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Grants

Grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the Charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charitable incorporated organisation becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable incorporated organisation after deducting all of its liabilities.

2 Income from donations and legacies

	Unrestricted funds		Total 31 December 2024	Total December 2023
	General £	Restricted funds £	£	£
Donations and legacies;				
Donations from individuals	12,319	-	12,319	20,948
Gift aid reclaimed	2,365	-	2,365	3,335
	-	-	-	-
	<u>14,684</u>	<u>-</u>	<u>14,684</u>	<u>24,283</u>

3 Income from other trading activities

	Total 31 December 2024	Total 31 December 2023
	£	£
Events income;		
Other events income	-	309
	<u>-</u>	<u>309</u>

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

4 Expenditure on raising funds

	Unrestricted funds		Total	Total
	General £	Restricted funds £	31 December 2024 £	31 December 2023 £
Costs of trading activities	1,572	-	1,572	1,240
	<u>1,572</u>	<u>-</u>	<u>1,572</u>	<u>1,240</u>

5 Expenditure on charitable activities

Note	Unrestricted funds		Total	Total
	General £	Restricted funds £	31 December 2024 £	31 December 2023 £
Research and patient advocacy	7,482	-	7,482	-
Allocated support costs	4,814	5,847	10,661	7,960
Governance costs	750	-	750	750
	<u>13,046</u>	<u>5,847</u>	<u>18,893</u>	<u>8,710</u>

6 Analysis of governance and support costs

Note	Restricted funds General £	Total 31 December 2024 £	Total 31 December 2023 £
Governance costs			
Independent examiner fees	-	-	-
Other fees paid to examiners	750	750	750
	<u>750</u>	<u>750</u>	<u>750</u>

7 Trustees

No trustees, nor any persons connected with them, have received any remuneration from the Charity during the year.

No trustees received any other benefits from the charity during the year.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

8 Independent examiner's remuneration

	Total 31 December 2024 £	Total 31 December 2023 £
Other fees to examiners		
The examining of accounts of any associate of the charity	750	750
	<u>750</u>	<u>750</u>

9 Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

10 Creditors: amounts falling due within one year

	Total 31 December 2024 £	Total 31 December 2023 £
Accruals	<u>750</u>	<u>750</u>

11 Funds

	Balance at 1 January 2024 £	Incoming resources £	Resources expended £	Balance at 31 December 2024 £
Unrestricted funds				
General	31,610	14,684	(14,618)	31,676
Restricted funds	5,847	-	(5,847)	-
Total funds	<u>37,457</u>	<u>14,684</u>	<u>(20,465)</u>	<u>31,676</u>

	Balance at 1 January 2023 £	Incoming resources £	Resources expended £	Balance at 31 December 2023 £
Unrestricted funds				
General	14,551	24,592	(7,533)	31,610
Restricted funds	8,264	-	(2,417)	5,847
Total funds	<u>22,815</u>	<u>24,592</u>	<u>(9,950)</u>	<u>37,457</u>

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2024

12 Analysis of net assets between funds

	Unrestricted funds		2024 Total funds
	General £	Restricted funds £	£
Current assets	32,426	-	32,426
Current liabilities	(750)	-	(750)
Total net assets	31,676	-	31,676

	Unrestricted funds		2023 Total funds
	General £	Restricted funds £	£
Current assets	29,943	8,264	38,207
Current liabilities	(750)	-	(750)
Total net assets	29,193	8,264	37,457

13 Related party transactions

There were no related party transactions during the year.

LOBULAR BREAST CANCER UK

England & Wales - Charity number 1191402

Accounts

LOBULAR BREAST CANCER UK

(A Charitable Incorporated Organisation)

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

**Working together,
we can all live well**

www.lobularbreastcancer.org.uk



LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

Contents

Reference and Administrative Details	1-2	
Chair's Statement		3
Trustees Report	4-13	
Responsibilities of the Trustees	14	
Chartered Accountants' report	15	
Statement of financial activities	16	
Balance sheet	17	
Notes to the Financial Statements	18 - 23	

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2023

Registered Charity Name:

Lobular Breast Cancer UK

Charity Registration:

22 September 2020

**Charitable Incorporated Organisation
Registration No:**

CE023524

Charity Registration No:

1191402

The Charity is incorporated in England and Wales

Registered Office

83 Ducie Street
Manchester M1 2JQ

Trustees

Emma Amos
Danni Buck (retired 19 May 2023)
Helen Coulthard
Elaine Nangle
Claire Turner (Chair)

Patrons

Josie Lloyd
Dame Martina Milburn DCVO CBE

Scientific & Medical Advisory Group (SMAG)

- Professor Val Brunton (University of Edinburgh)
- Dr Soujanya Gadde Consultant Radiologist (The Nightingale Centre Wythenshawe Hospital, Manchester)
- Charlotte Milns Senior Breast Care Nurse (The Nightingale Centre, Wythenshawe Hospital, Manchester)
- Dr Sankari Nagarajan (The University of Manchester)
- Dr Alicia Okines, Medical Oncologist (Royal Marsden Hospital, London)
- Professor Elinor Sawyer, Professor of Clinical Oncology and Breast Cancer Genetics (King's College London & Guys & St Thomas Foundation Trust)

**LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2023**

Accountant

Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Bankers

The Co-operative Bank
P.O. Box 250
Delf House
Southway
Skelmersdale
WN8 6WT

Email:

info@lobularbreastcancer.org.uk

Website:

lobularbreastcancer.org.uk

Social Media:

@LobularBCUK

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Chair's Statement
FOR THE YEAR ENDED 31 DECEMBER 2023

2023 has been an exciting and busy year for Lobular Breast Cancer UK (LBCUK).

In our commitment to being driven by evidence and to pushing forward research into Lobular Breast Cancer we collaborated with clinicians and researchers across the UK and globally on much needed research into this distinct disease.

We brought together clinicians, researchers and patient advocates involved in Lobular research setting up the first Lobular UK Research Network to increase collaborative working and knowledge sharing across the UK.

We continued to deliver our National Lottery Community Fund programme with 15 women attending Lobular Wellbeing Workshops in Manchester and Nottingham.

Our relationship with the key breast cancer charities was further enhanced through the inclusion of Ruth Warden and Darlaine Honey, two of our founders, in Breast Cancer Now's patient campaigns, and we supported the updating of their Lobular patient information leaflet.

I had the pleasure of working globally with clinicians, researchers and patient advocates from around the world on the International Invasive Lobular Carcinoma Symposium Planning Committee hosted in Pittsburgh. LBCUK presented our research produced in collaboration with Dr Helen Coulthard, LBCUK Trustee, Lobular patient advocate and Health Psychologist at De Montfort University, exploring the psychological impacts of having Lobular tumours missed on mammogram.

We delivered our first Breast Cancer Awareness Month (BCAM) online campaign in October, "Are you aware?" working to dispel the myths around Lobular Breast Cancer and increasing knowledge and information amongst the general public. During BCAM Emma Amos, a LBCUK Trustee, was nominated for Woman of the Year 2023 for her work with the charity.

Building on our first *Walking our Mammaries* fundraising challenge in 2022, we ran a smaller weekend event for women with a Lobular diagnosis tackling Mam Tor and the mounds of the Peak District. Supporters took part in our first virtual fundraisers in the *Walking our Mammaries* summer challenge.

Recognising the need to enhance our skills, we launched a Trustee recruitment campaign to improve our governance and bring more resource into the charity. Four new Trustees will be beginning with the charity in 2024 bringing experience in running charities, communications, clinical knowledge and understanding of psychosocial impacts of a cancer diagnosis.

Our Board joins me in thanking our Patrons Josie Lloyd and Dame Martina Milburn; our Scientific and Medical Advisory Group; BBC News' Jane Hill for participating in our films; our families, friends, supporters, funders and partners especially our international partners Lobular Breast Cancer Alliance, the European Lobular Breast Cancer Consortium, European Lobular Breast Cancer Advocates and Lobular Ireland.

I want to personally thank our Trustees Emma Amos, Danni Buck, Helen Coulthard, and Elaine Nangle, and our Founder members Darlaine Honey, Lorna McHattie, and Ruth Warden for their continued commitment, energy and passion for developing our charity, whilst also living with a Lobular Breast Cancer diagnosis.

2024 will be a year of action and change for us at LBCUK as we welcome our new Trustees on board and begin work to make real clinical changes as we start our Treatment Guidelines campaign to improve outcomes for patients.

Finally we want to remember everyone who has died this year of Lobular Breast Cancer. One person is too many. Our thoughts and love extend to their families and friends. We commit to working together to ensure that in the future, everyone with a Lobular diagnosis lives and lives well.

Thank you

Claire Turner

Chair

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees have pleasure in presenting their report and the financial statements of the Charity for the year ended 31 December 2023.

LBCUK'S CHARITABLE OBJECTS

The object of the CIO is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around lobular breast cancer.

LOBULAR BREAST CANCER UK

Lobular Breast Cancer UK is a patient-led voluntary charity registered as a Charitable Incorporated Organisation on 22 September 2020 and launched on 22 September 2021.

We established in response to a lack of information and appropriate treatments for patients diagnosed with Lobular Breast Cancer.

Lobular Breast Cancer is a sub-type of breast cancer that makes up around 15% of all breast cancers diagnosed and is the second most common form of the disease.

The key challenges we face include:

- Lobular is a distinct disease that behaves differently from other breast cancers. However current UK guidelines, and many clinicians, do not recognise it as a distinct disease;
- Lobular tumours grow like a spider's web in straight lines rarely forming a lump. This can make it hard to see on scans. As a result, we are often diagnosed at a more advanced stage of the disease and with larger tumours;
- a lack of understanding how Lobular grows, spreads, and responds to treatment. It is an under-researched and under-funded disease;
- ensuring that everyone is told that they have Lobular Breast Cancer, not simply breast cancer. It is impossible to make the best treatment decisions if you do not know that you have Lobular;
- there are no treatments specifically targeted for Lobular;
- more research is needed into the psychological impacts of a Lobular diagnosis.

We are led by people with a lived experience of Lobular Breast Cancer. This ensures that patient needs always remain at the forefront of our work.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

OUR PURPOSE

Working together, we can all live well.

OUR VISION

Lobular Breast Cancer is understood comprehensively, diagnosed effectively, treated appropriately, and patients have access to support across the UK.

OUR VALUES

- The patient is always first.
- We are bold and courageous in speaking up for ourselves and anyone affected by Lobular Breast Cancer.
- We commit to reducing the isolation and fear of a Lobular Breast Cancer diagnosis.
- We are evidence based in all our communications and information.
- We act compassionately towards everyone, recognising and accepting our different experiences and beliefs, and treating each other with care, consideration and respect.
- We are stronger together, collaborating and sharing learning with all our stakeholders.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

HOW WE DELIVERED PUBLIC BENEFIT IN 2023


87%
of respondents said we increased their knowledge & understanding of Lobular Breast Cancer*




16,486
people visited our LBCUK website



187k
people reached through our social media



66%
of respondents said we reduced their isolation & fear following a Lobular diagnosis*



1,490
downloads of information from our website



"Supportive, informative, safe. Great to meet people in person who understand what you are going through."

"I found it inspiring and exhilarating to meet other women in a safe space."

Participants in our Lobular Wellbeing Workshops

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2023

INFORMATION and EDUCATION

We advance awareness and understanding of Lobular Breast Cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

Our website and social media continue to be the primary methods of disseminating evidence-based and patient-focused information about Lobular Breast Cancer.

During 2023:

- we delivered a webinar on the experience of Lobular patients to Breast Cancer Nurses in Manchester University NHS Foundation Trust;
- we collaborated with Breast Cancer Now to update their Lobular Breast Cancer patient leaflet;
- during Breast Cancer Awareness Month we ran our Are You Aware? campaign to increase knowledge and information about Lobular;
- we partnered with Lobular Breast Cancer Alliance to co-facilitate the International ILC Symposium Patient Advocate online research session;
- we continued our #22ADayUK campaign raising awareness of the number of people diagnosed with Lobular Breast Cancer every day in the UK.



POLICY & TREATMENT GUIDELINES

During our first stakeholder survey conducted in 2023, changing the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Network (SIGN) breast cancer guidelines was a key priority for respondents. NICE and SIGN guidelines determine how Lobular patients are treated in our hospitals.

Despite the latest research indicating that Lobular is a distinct sub-type of breast cancer which presents, grows and responds differently to some treatments, this is not reflected in the guidelines for treating Lobular across the UK. (Oesterreich et al. 2022)¹.

¹ Oesterreich, S. et al. *Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer*. Journal of the National Cancer Institute (2022) <https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac157/6758318?login=false>

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2023

In 2023, we began planning a new campaign to make these changes with support from the Policy teams of Breast Cancer Now and Cancer Research UK. We will launch the campaign in 2024.

In addition, to raise the profile of Lobular in health policy decision making we contributed to the following bodies and activities:

- as a member of *NICE's Voluntary & Community Forum*;
- attending the *All-Party Parliamentary Breast Cancer Group* discussion on the future of the breast screening programme representing Lobular patients.

RESEARCH



We developed new and enhanced our on-going relationships with the leading Lobular clinicians and researchers across the UK and internationally.

We launched and co-ordinate the first **Lobular Research Network UK** to build collaboration and relationships between researchers, health professionals and patient advocates from across the UK. By bringing together a diverse range of individuals we plan to action real change in knowledge, understanding and treatment of Lobular across the four countries.

Our Chair continued her roles as UK Patient Advocate with the European Lobular Breast Cancer Consortium (ELBCC), the European Lobular Breast Cancer Advocates and GlobMob, the international Lobular advocate group. She now sits as a member of NICE's Voluntary & Community Forum.

A collaborative study in partnership with De Montfort University, *Missed Cancers: Lobular Breast Cancer that has been missed on screening*, was presented as a poster at the annual International Invasive Lobular Carcinoma (ILC) Symposium in Pittsburgh during September.

In addition,

- research we supported as partner patient advocates was successful in securing a £250,000 grant for Lobular research at Guy's Hospital and King's College London from Breast Cancer Now: *Personalised Therapies for Relapsed Lobular Breast Cancer Patients*²;
- we worked with the Royal Marsden to ensure that eligible Lobular patients know about the opportunity to participate in the TRAK-ER liquid biopsy trial;
- our Chair was Co-author on a poster with the European Lobular Breast Cancer Advocates presented at San Antonio Breast Cancer Symposium *Enhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer. Unique Challenges across European Countries.*

² <https://breastcancer.org/breast-cancer-research/our-research-projects/personalised-therapies-relapsed-lobular-breast-cancer-patients>

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2023

INTERNATIONAL ILC SYMPOSIUM

We took an active and leading role at the International Invasive Lobular Carcinoma (ILC) Symposium in Pittsburgh in September 2022.

Our Chair was funded as part of the organising committee and we were able to send one further LBCUK Patient Advocate through our own funds. We presented on two of the panel sessions and presented a collaborative poster in partnership with De Montfort University on the psychological impact of Lobular tumours being missed on mammogram.

The ILC Symposium is the only Lobular focused symposium in the world. It brings together clinicians, researchers and patient advocates all committed to researching, understanding and identifying the most effective treatment for Lobular Breast Cancer. Collaboration and collective working are a key tool for achieving global change.

SUPPORT

In response to three PPI workshops we co-facilitated in partnership with De Montfort University's (DMU) Health Psychology Department we worked on the development of digital information cards specific for Lobular patients. They will provide information and questions that help patient discussions with medical professionals during the different stages of diagnosis and be published in 2024.

We continued to deliver our National Lottery funded Lobular Wellbeing Workshops for women with a Lobular diagnosis, providing events in Manchester and Nottingham. A big thank you to Maggie's in Nottingham who provided us with such a beautiful, relaxing and safe venue to host the workshop, and our Patron Josie Lloyd who led elements of our Manchester workshop.



Our monitoring MRI template letter continues to be downloaded from our website with over 1,000 women accessing it. The letter has been successful in enabling women to access supplementary imaging to monitor their breasts following their initial treatment for a primary Lobular Breast Cancer. It demonstrates patient concerns about the efficacy of current monitoring available for Lobular.

In addition, we continue to respond to hundreds of questions and concerns from the public through our email, social media and direct mail. We work to ensure that anyone with a Lobular diagnosis receives evidence-based information about Lobular Breast Cancer and can also be directed to the most appropriate form of professional support.

INCOME GENERATION

We hosted a smaller second weekend *Walking our Mammaries* event during the year. Eight women tackled the Mam Tor ridgeline in the Peak District raising funds for the charity. During the summer, a number of

people took part in the first virtual *Walking our Mammaries* fundraiser. Supporters selected their own mammary mound or mountain anywhere in the UK and walked on behalf of LBCUK.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023



A huge thank you goes to everyone who has raised funds for us throughout the year.

FINANCIAL REVIEW

As a volunteer run charity, we currently have few overheads.

Our annual budgets are approved and monitored by the Board at each meeting. Any variances from the proposed budget are highlighted and discussed at the meetings.

In the opinions of the Trustees, the Charitable Company's assets are sufficient to fulfil the obligations of the Charity.

RESERVES POLICY

During 2023, following the first full year of operations in 2022, the Board reviewed and revised our Reserves Policy from a zero Reserves Policy.

We will maintain our unrestricted reserves at a level which is at equivalent to between three - six months' operational expenditure with a target of £4,000. We have also allocated £10,000 unrestricted reserves for the financial year 2024 of £10,000, towards enhancing and ensuring the GDPR compliance of our IT systems, training for Trustees and volunteers and the potential to pay for selective specialist functions such as administrative support, and the development of our information and communications materials. At the balance sheet date the charity held total funds of £37,457 (2022: £22,815) of which £5,847 (2022: £8,264) were held in restricted funds leaving £31,610 (2022: £14,551) in free reserves.

Due to the success of funding during 2022 and limited overheads, we have focused on 2023 as a year to implement and utilise our financial resource to enhance the public benefit that we offer as an organisation, rather than focus on a further fundraising drive.

This focus will continue into 2024 as we focus on utilising our resources for public benefit and our targeted new Treatment Guidelines campaign to improve clinical outcomes for Lobular patients.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

REVIEW OF RISKS

The Trustees have considered the major risks facing the charity and have put in place appropriate policies and procedures to mitigate them.

The primary risk to the charity is the growing demand for our services and the lack of personnel resource to meet this demand. A Trustee recruitment process has taken place during 2023 recognising a risk to the charity in the lack of Trustee diversity, missing key skills or loss of existing trustees impacting on good governance. New Trustees will be appointed in 2024.

FUTURE PLANS

Our future plans focus on building activity to achieve the five key strategic aims of our charity.

AIM 1: INFORMATION & EDUCATION: we advance education and understanding of Lobular Breast Cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

AIM 2: POLICY & TREATMENT GUIDELINES: we will work with partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries.

AIM 3: RESEARCH: we will work with patients, clinicians and health professionals to ensure that research and trials conducted for Lobular Breast Cancer meet the needs of patients, and we will raise funds for research projects.

AIM 4: SUPPORT: we provide routes to appropriate support and connection for patients, reducing the isolation and fear of a Lobular Breast Cancer diagnosis.

AIM 5: OUR IMPACT: we continue to build LBCUK as an effective, professional and sustainable independent charity, increasing our impact.

A key focus for 2024 and beyond is the delivery of our new campaign to gain recognition of Lobular Breast Cancer/Invasive Lobular Carcinoma (ILC) as a distinct disease in the Breast Cancer Treatment Guidelines for NICE and SIGN.

We will continue to build stronger collaborative relationships across the UK and internationally with other Lobular specific and breast cancer charities, and all relevant stakeholders.

There is a real desire for Lobular patients to come together and meet others experiencing this distinct disease. During 2024, we will be collaborating with Future Dreams to establish in person and online meet up workshops for people to come together, share their experiences and provide support for each other.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

STRUCTURE GOVERNANCE & MANAGEMENT

GOVERNING DOCUMENT

The Charity is a Charitable Incorporated Organisation and is governed by its Foundation CIO Constitution. It is registered as a CIO with the Charity Commission for England & Wales.

TRUSTEE INDUCTION, RECRUITMENT & TRAINING

The Trustees are collectively known as the Board.

Trustees are appointed by invitation from the existing Trustees and through an open recruitment process, following a majority vote of the Trustees of the Charity.

Invited potential Trustees are requested to either provide a CV and covering letter/three minute short film for consideration by the Board or to complete a formal application process for open recruitment. All Trustees are interviewed by a panel of at least two Trustees and a recommendation is made to the Board if they are determined to be suitable to be invited as a Trustee.

New Trustees are provided with a copy of the Charity Commission's leaflet for new Trustees, 'The Essential Trustee: what you need to know, what you need to do' (CC3), a copy of our Constitution, a copy of the Charity Governance Code, recent Board minutes and latest Annual Report and Accounts. They also receive a briefing and annual reviews with the current Chair.

ORGANISATION

The Charity is governed by the Board and managed by the charity's Trustees and four voluntary Founders. The Trustees who have acted during the year are listed above. Four of the listed Trustees are also Founders of the charity.

Trustees meet approximately 4 - 5 times a year to discuss and agree on matters of charity governance, policy and strategy. Further ad hoc meetings are organised as required to address specific issues. Trustees develop strategies to increase charity awareness, widen reach across our stakeholders and build the sustainability of this new and growing organisation.

These meetings also include budget reports and cash flow. Any changes in strategy are discussed, amended and when agreed, adopted as written charity policy by Trustees.

Where risks are identified, steps are taken to mitigate these risks, including reference to how the charity has met its charitable aims in the advancement of education, training, support, research and advocacy. Any actions taken are then reported on and reviewed at subsequent meetings.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2023

The implementation of policies and strategies is delivered operationally by the five Trustees and the three volunteer Founder Members. To ensure that our activities are evidence based and reflect the latest scientific knowledge about lobular breast cancer. We have a Scientific and Medical Advisory Group involving six respected clinicians and researchers in the field of Lobular Breast Cancer.

We have no premises and are based across the UK.

All Trustees and relevant volunteers participate in relevant training programmes.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Responsibilities of the Trustees
FOR THE YEAR ENDED 31 DECEMBER 2023

RESPONSIBILITIES OF THE TRUSTEES

Under charity law, the Trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the CIO constitution. It is also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Signed by order of the Trustees



Claire Turner
Chair of Trustees
27 October 2024

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Chartered Accountants Report to the trustees
FOR THE YEAR ENDED 31 DECEMBER 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Lobular Breast Cancer UK for the year ended 31 December 2023 as set out on pages 9 to 18 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW) we are subject to its ethical and other professional requirements which are detailed at <http://www.icaew.com/en/members/regulations-standards-and-guidance>.

This report is made solely to the board of directors of Lobular Breast Cancer UK, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Lobular Breast Cancer UK and state those matters that we have agreed to state to the board of directors of Lobular Breast Cancer UK, as a body, in this report, in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Lobular Breast Cancer UK and its board of directors as a body for our work or for this report.

It is your duty to ensure that Lobular Breast Cancer UK has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and of Lobular Breast Cancer UK. You consider that Lobular Breast Cancer UK is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Lobular Breast Cancer UK. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts

Beever and Struthers

Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Date: 28 October 2024

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Statement of Financial Activities
(Including Income and Expenditure Account and Statement of Total
Recognised Gains and Losses)
FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	Unrestricted funds £	Restricted funds £	Total 31 December 2023 £
Income and Endowments from:				
Donations and legacies	3	24,283	-	24,283
Other trading activities	4	309	-	309
Total income		<u>24,592</u>	-	<u>24,592</u>
Expenditure on:				
Raising funds	5	(1,240)	-	(1,240)
Charitable activities	6	(6,293)	(2,417)	(8,710)
Total expenditure		<u>(7,533)</u>	<u>(2,417)</u>	<u>(9,950)</u>
Net income / (expenditure)		<u>17,059</u>	<u>(2,417)</u>	<u>14,642</u>
Net movement in funds		17,059	(2,417)	14,642
Reconciliation of funds				
Total funds brought forward		<u>14,551</u>	8,264	<u>22,815</u>
Total funds carried forward	12	<u>31,610</u>	<u>5,847</u>	<u>37,457</u>

	Note	Unrestricted funds £	Restricted funds £	Total 31 December 2022 £
Income and Endowments from:				
Donations and legacies	3	19,951	9,952	29,903
Total income		<u>19,951</u>	<u>9,952</u>	<u>29,903</u>
Expenditure on:				
Raising funds	5	(4,080)	-	(4,080)
Charitable activities	6	(3,668)	(1,688)	(5,356)
Total expenditure		<u>(7,748)</u>	<u>(1,688)</u>	<u>(9,436)</u>
Net income		<u>12,203</u>	<u>8,264</u>	<u>20,467</u>
Net movement in funds		12,203	8,264	20,467
Reconciliation of funds				
Total funds brought forward		<u>2,348</u>	-	<u>2,348</u>
Total funds carried forward	12	<u>14,551</u>	<u>8,264</u>	<u>22,815</u>

All of the Charity's activities derive from continuing operations during the above two periods.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
(Registration number: CE023524)
Balance Sheet
AS AT 31 DECEMBER 2023

	Note	31 December 2023 £	31 December 2022 £
Current assets			
Cash at bank and in hand		38,207	24,375
Creditors: Amounts falling due within one year	11	(750)	(1,560)
Net assets		37,457	22,815
Funds of the Charity:			
Restricted funds		5,847	8,264
Unrestricted income funds			
Unrestricted funds		31,610	14,551
Total funds	12	37,457	22,815

The financial statements on pages 16 to 23 were approved by the trustees, and authorised for issue on 27 October 2024 and signed on their behalf by:



Claire L Turner
Trustee

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Charity status

The Charity is a Charitable Incorporated Organisation, incorporated in England and Wales.

The address of its registered office is:

83 Ducie Street
Manchester
M1 2JQ

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") the Charities Act 2011, and Charities (Accounts and Reports) Regulations 2008, as well as the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" 2019.

Basis of preparation

Lobular Breast Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost.

Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the Charity.

Exemption from preparing a cash flow statement

The Charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the Charity before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that these conditions will be fulfilled in the reporting period.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

Grants receivable

Grants are recognised when the Charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the Charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Grants

Grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the Charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charitable incorporated organisation becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable incorporated organisation after deducting all of its liabilities.

3 Income from donations and legacies

	Unrestricted funds		Total 31 December 2023	Total December 2022
	General	Restricted		
	£	funds	£	£
		£		
Donations and legacies;				
Donations from individuals	20,948	-	20,948	17,268
Gift aid reclaimed	3,335	-	3,335	2,683
Grants	-	-	-	9,952
	<u>24,283</u>	<u>-</u>	<u>24,283</u>	<u>29,903</u>

4 Income from other trading activities

	Total 31 December 2023	Total 31 December 2022
	£	£
Events income;		
Other events income	309	-
	<u>309</u>	<u>-</u>

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

5 Expenditure on raising funds

	Unrestricted funds		Total	Total
	General	Restricted	31 December	31 December
	£	funds	2023	2022
		£	£	£
Events and conferences	1,240	-	1,240	4,080
	1,240	-	1,240	4,080

6 Expenditure on charitable activities

		Unrestricted funds		Total	Total
	Note	General	Restricted	31 December	31 December
		£	funds	2023	2022
			£	£	£
Charitable activities		5,543	2,417	7,960	3,076
Governance costs	7	750	-	750	2,280
		6,293	2,417	8,710	5,356

7 Governance Costs

	Total	Total
	31 December	31 December
	2023	2022
	£	£
Independent examiner fees:		
Examination of the financial statements	-	780
Other fees paid to examiners	750	1,500
	750	2,280

8 Trustees

No trustees, nor any persons connected with them, have received any remuneration from the Charity during the year.

One trustee was reimbursed expenses totalling £76 (2022: £76). No trustees received any other benefits from the charity during the year.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

9 Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

10 Creditors: amounts falling due within one year

	31 December 2023	31 December 2022
	£	£
Accruals	750	1,560

11 Funds

	Balance at 1 January 2023	Incoming resources	Resources expended	Balance at 31 December 2023
	£	£	£	£
Unrestricted funds				
General	14,551	24,592	(7,533)	31,610
Restricted funds	8,264	-	(2,417)	5,847
Total funds	22,815	24,592	(9,950)	37,457

	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 31 December 2022
	£	£	£	£
Unrestricted funds				
General	2,348	19,951	(7,748)	14,551
Restricted funds	-	9,952	(1,688)	8,264
Total funds	2,348	29,903	(9,436)	22,815

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

12 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	2023 Total funds
	General £	£	£
Current assets	32,360	5,847	38,207
Current liabilities	(750)	-	(750)
Total net assets	31,610	5,847	37,457

	Unrestricted funds	Restricted funds	2022 Total funds
	General £	£	£
Current assets	16,111	8,264	24,375
Current liabilities	(1,560)	-	(1,560)
Total net assets	14,551	8,264	22,815

13 Related party transactions

There were no related party transactions during the year.

LOBULAR BREAST CANCER UK

England & Wales - Charity number 1191402

Accounts




LOBULAR BREAST CANCER UK

(A Charitable Incorporated Organisation)

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022



Charitable incorporated organisation registration number: CE023524

Charity registration number: 1191402

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

Contents

Reference and Administrative Details.....	1-2
Chair’s Statement.....	3
Trustees Report.....	4-17
Independent Examiners report.....	18
Statement of financial activities.....	19
Balance sheet.....	20
Notes to the Financial Statements.....	21-27

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2022

Registered Charity Name:

Lobular Breast Cancer UK

Charity Registration:

22 September 2020

**Charitable Incorporated Organisation Charity Registration No:
Registration No:**

CE023524

1191402

The Charity is incorporated in England and Wales

Registered Office

83 Ducie Street
Manchester M1 2JQ

Trustees

Emma Amos
Danni Buck
Helen Coulthard
Elaine Nangle (appointed 1 January 2022)
Claire Turner (Chair)

Patrons

Josie Lloyd
Dame Martina Milburn DCVO CBE

Scientific & Medical Advisory Group (SMAG)

- Professor Val Brunton (University of Edinburgh)
- Dr Soujanya Gadde Consultant Radiologist (The Nightingale Centre Wythenshawe Hospital, Manchester)
- Charlotte Milns Senior Breast Care Nurse (The Nightingale Centre Wythenshawe Hospital, Manchester)
- Dr Sankari Nagarajan (The University of Manchester)
- Dr Alicia Okines, Medical Oncologist (Royal Marsden Hospital, London); and
- Professor Elinor Sawyer, Professor of Clinical Oncology and Breast Cancer Genetics (King's College London & Guys & St Thomas Foundation Trust)

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Reference and Administrative Details
FOR THE YEAR ENDED 31 DECEMBER 2022

Independent Examiner

Helen Binns
Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Bankers

The Co-operative Bank
P.O. Box 250
Delf House
Southway
Skelmersdale
WN8 6WT

Email:

info@lobularbreastcancer.org.uk

Website:

lobularbreastcancer.org.uk

Social Media:

@LobularBCUK

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Chair's Statement
FOR THE YEAR ENDED 31 DECEMBER 2022

2022 has been our first full year of operations since the launch of Lobular Breast Cancer UK as a new charity in September 2020.

A major step forward was the development of new income streams that enabled us to begin working towards our strategic goals. In February, we secured our first grant from the National Lottery for new educational resources and workshops to support women with a Lobular diagnosis.

During May, 8 women participated in our unique challenge *Walking our Mammaries*. They tackled mountains in Scotland named after breasts, raising over £12,000 to support our work.

We launched our first public awareness campaign #22ADayUK, visually representing the 22 women who are diagnosed with Lobular every day in the UK. Groups from across the UK helped to share our message including actors, sea kayakers, Civil Servants and cold water swimmers.

In June we received the devastating news that Leigh Pate, our leading international Lobular patient advocate, had died from fallopian cancer. Leigh led on the founding of the Lobular Breast Cancer Alliance in the United States and provided huge support in setting up LBCUK. She reached thousands of people across the world transforming Lobular advocacy. We honour her incredible legacy by continuing to drive forward for better understanding and treatments in Lobular Breast Cancer.

As the year progressed, demand for our services increased as knowledge of our charity grew. We launched two new research studies on patient needs in partnership with De Montfort University and established our role globally, participating in the International Invasive Lobular Carcinoma (ILC) Symposium.

We are delighted to welcome Dame Martina Milburn, former Chief Executive of The Prince's Trust Worldwide, as a new Patron. Martina's experience and connections are already helping us to develop new beneficial collaborations with key organisations.

Our Board joins me in thanking our Patrons Josie Lloyd and Martina; our Scientific and Medical Advisory Group; BBC News' Jane Hill for participating in our films; our families, friends, supporters, funders and partners especially our international partners Lobular Breast Cancer Alliance, Lobular Ireland, and the European Lobular Breast Cancer Consortium.

I want to personally thank our Founding Trustees Emma Amos, Danni Buck, Helen Coulthard, and Elaine Nangle, and our Founder members Darlaine Honey, Lorna McHattie, Kirstin Spencer and Ruth Warden for their continued commitment and passion for developing our charity, whilst living with a Lobular Breast Cancer diagnosis.

We look forward to 2023 with renewed vigour and a commitment to unlocking the primary challenges presented by the distinct disease that is Lobular Breast Cancer.

Thank you

Claire Turner

Chair

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees have pleasure in presenting their report and the financial statements of the Charity for the year ended 31 December 2022.

LBCUK'S CHARITABLE OBJECTS

The object of the CIO is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around lobular breast cancer.

LOBULAR BREAST CANCER UK

Lobular Breast Cancer UK (LBCUK) is a patient-led voluntary charity registered as a Charitable Incorporated Organisation on 22 September 2020 and launched on 22 September 2021.

We established in response to a lack of information and appropriate treatments for patients diagnosed with Lobular Breast Cancer.

Lobular Breast Cancer is a sub-type of breast cancer that makes up 15% of all breast cancers diagnosed and is the second most common form of the disease.

The key challenges we face include:

- Lobular is a distinct disease that behaves differently from other breast cancers. However current UK guidelines, and many clinicians, do not recognise it as a distinct disease;
- Lobular tumours grow like a spider's web in straight lines rarely forming a lump. This can make it hard to see on scans. As a result, we are often diagnosed at a more advanced stage of the disease and with larger tumours;
- a lack of understanding how Lobular grows, spreads, and responds to treatment. It is an under-researched and under-funded disease;
- ensuring that everyone is told that they have Lobular Breast Cancer, not simply breast cancer. It is impossible to make the best treatment decisions if you do not know that you have Lobular;
- there are no treatments specifically targeted for Lobular;
- more research is needed into the psychological impacts of a Lobular diagnosis.

We are led by people with a lived experience of lobular breast cancer. This ensures that patient needs always remain at the forefront of our work.

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2022

OUR PURPOSE

Working together, we can all live well.

OUR VISION

Lobular Breast Cancer is understood comprehensively, diagnosed effectively, treated appropriately, and patients have access to support across the UK.

OUR VALUES

- The patient is always first.
- We are bold and courageous in speaking up for ourselves and anyone affected by Lobular Breast Cancer.
- We commit to reducing the isolation and fear of a Lobular Breast Cancer diagnosis.
- We are evidence based in all of our communications and information.
- We act compassionately towards everyone, recognising and accepting our different experiences and beliefs, and treating each other with care, consideration and respect.
- We are stronger together, collaborating and sharing learning with all of our stakeholders.



Our first Lobular Wellbeing Workshop at Maggie's Barts, November 2022

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2022

HOW WE DELIVERED PUBLIC BENEFIT IN 2022

- **5,000 new individuals** reached through our website
- **Over 8,000 views** of our Lobular information short films
- **Reached 182,000 people** across social media
- **Launched two Lobular specific studies** focusing on patient experiences and priorities
- 87% of people state our work has **increased their knowledge of Lobular**^{*1}
- 66% of people state our work has **reduced their isolation and fear about a Lobular diagnosis***
- 59% of people state our work has **helped build their confidence** in speaking with their medical team about Lobular*
- **50 Lobular patients participated in a study** to identify patient concerns and priorities
- **Collaborated with over 100 Lobular clinicians, researchers and patient advocates** at the International Invasive Lobular Symposium **presenting 2 talks, 1 poster and a short film**

INFORMATION and EDUCATION

We advance awareness and understanding of lobular breast cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

Our website continues to be the primary method of disseminating evidence-based and patient-focused information about Lobular Breast Cancer.

During 2022:

- 5,000 new visitors came to the LBCUK website over the last 6 months of the year (data only available for this time period);
- over 8,000 views of short films we created for our YouTube channel representing the patient experience and conversations with experts;
- we launched our #22ADay UK campaign visually demonstrating the 22 women diagnosed in the UK with Lobular Breast Cancer every day. We were supported by participants from Shakespeare's Globe theatre, Colwyn Canoe Club,
- production company AfterParty Studios funded a short film *Tits Up* that documented our *Walking our Mammaries* preparations and shared the difficulties, fears and hopes of the women following a Lobular diagnosis;
- we presented to Breast Cancer Now's Helpline Nurses about the concerns of Lobular patients and what support they needed from nurses;
- we collaborated with Breast Cancer Now nurses on an Instagram Live about Lobular;
- we participated in an international collaborative campaign to increase knowledge about breast cancer sub-types, especially Lobular, during Breast Cancer Awareness Month;
- our Chair co-facilitated the International ILC Symposium Patient Advocate online

¹ * LBCUK Annual Survey

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022



Groups participating in our #22ADayUK campaign (from left to right): Hele Bay Merbabes sea swimmers, family and friends of *Walking our Mammaries* participants, cast and crew from *Noises Off* production

POLICY & TREATMENT GUIDELINES

During 2022, we began learning how to navigate the complexities of health policy, government consultations and particularly the National Institute for Health and Care Excellence (NICE) guidelines. NICE guidelines determine how Lobular patients are treated in our hospitals.

We participated in the following consultations representing the patient voice:

- UK Government's *10-year Cancer Consultation*;
- *Developing NICE guidelines: the manual*;
- *NICE Medtech Innovation Briefing - patient perspective on contrast enhanced spectral mammography (CESM)*.

RESEARCH

We developed new and enhanced our on-going relationships with the leading Lobular clinicians and researchers across the UK and internationally. Lobular specific research is needed to better understand the disease; develop targeted treatments; and to evidence requests for Lobular specific clinical guidelines.

Our Chair continued her roles as UK Patient Advocate with the European Lobular Breast Cancer Consortium (ELBCC) Patient Advocacy group and GlobMob, the international Lobular advocate group.

Setting Priorities for lobular breast cancer research: a patient-led consensus study, our research study launched in 2021 in partnership with De Montfort University, continued with 50 participating individuals. An additional round of questions was conducted to identify the most important priorities for patients, delaying publication until 2023.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

A further study, developed in partnership with De Montfort University MA student Victoria Rake, aims to understand the experience of having a Lobular cancer that has been missed on mammogram: *Missed Cancers: Lobular Breast Cancer that has been missed on screening.*

The building of relationships between patients and researchers is key to driving forward Lobular research. We hosted our first **LBCUK Research Partnership Day** with the University of Edinburgh. It involved Scottish patients, clinicians and researchers developing ideas to drive forward new partnerships and understanding of Lobular.

We collaborated on the International ILC Survey with patient advocates, clinicians and researchers from around the world, working to identify Lobular research priorities.²

During the year, we worked alongside UK and international Lobular experts in studies and disseminated opportunities to participate in research to patients by:



LBCUK Trustee Helen Coulthard (right) being shown lab techniques by Edinburgh Researcher Esmee

- supporting the submission of a successful £250,000 Lobular research bid to Breast Cancer Now *Personalised Therapies for Relapsed Lobular Breast Cancer Patients*³;
- sharing the CASCARA (**C**osts **A**nd **S**upportive **C**Are in **b**Reast **c**Ancer) participation opportunity to identify the hidden costs and supportive care needs associated with a breast cancer diagnosis;
- supporting the development of two Lobular specific funding submissions for an early career researcher and a clinical training fellowship;
- supporting the development of a Lobular imaging focused paper for metastatic disease;
- supporting a UK and the Netherlands collaborative research bid exploring a Lobular novel protein;
- our Chair representing the Lobular patient experience in an online Multi-Disciplinary Team training panel for the European Society of Surgical Oncology.

² https://aacrjournals.org/cancerres/article/83/5_Supplement/P6-05-10/717027

³ <https://breastcancer.org/breast-cancer-research/our-research-projects/personalised-therapies-relapsed-lobular-breast-cancer-patients>

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2022

International ILC Symposium

We took an active and leading role at the International Invasive Lobular Carcinoma (ILC) Symposium in Utrecht in September 2022. Our Chair was funded as part of the organising committee and we were able to send two further LBCUK Patient Advocates through our own funds.

Preliminary findings from our *Setting Priorities* study were presented as a poster. Our Chair spoke about the development of relationships with clinicians and researchers in the UK, and presented feedback from Leigh Pate and Steffi Oesterreich's published paper *How Researchers, Clinicians and Patients Advocates Can Accelerate Lobular Breast Cancer Research* (2021).⁴ Our *Tits Up* short film had its first public screening.



International ILC Symposium 2022 (left to right) Researcher Steffi Oesterreich, LBCUK Chair Claire Turner, Clinical Oncologist Dr Rachel Jankowitz, Breast Surgeon Dr Rita Mukhtar and LBCUK Trustee Emma Amos

SUPPORT

Recognising that we do not have the resources to provide individual and focused support for Lobular patients, our strategy focuses on ensuring professional breast cancer support services are up to date with the latest Lobular information and research, and their services can respond to the specific needs of Lobular patients.

In March 2022, three PPI workshops were facilitated in partnership with De Montfort University's (DMU) Health Psychology Department to identify patient areas of concern and need.

⁴ Leigh Pate et al. (2021) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268486/>

LOBULAR BREAST CANCER UK (A Charitable Incorporated Organisation) Trustees Report FOR THE YEAR ENDED 31 DECEMBER 2022

In response to these findings, further workshops were organised to co-create a series of digital postcards for patients. They will provide information and questions that help patient discussions with medical professionals during the different stages of diagnosis. Jo Taylor from [abcdiagnosis](https://www.abcdiagnosis.co.uk)⁵ was involved in the development of a card for metastatic disease. The work was funded by DMU and the National Lottery.

In October 2022, we presented to Breast Cancer Now's Helpline Nurses on Lobular Breast Cancer sharing the concerns faced by many women with a Lobular diagnosis. Breast Cancer Now put a new link to our website on their Lobular advice page and plans to involve us in their Lobular booklet review during 2023.

We delivered our first National Lottery funded Lobular Wellbeing Workshop for women with a Lobular diagnosis. A big thank you to Maggie's at Barts Hospital who provided us with such a beautiful, relaxing and safe venue to host the workshop, and our Patron Josie Lloyd who led elements of the day.

INCOME GENERATION

We hosted our pilot fundraising event *Walking our Mammaries*, a Scottish mountain challenge tackling peaks named after breasts. Eight women took part raising over £12,000 for the charity. Family and friends joined us for the final day and created one of our #22ADayUK campaign images.

During one *Walking our Mammaries* training weekends, film production company After Party Studios, funded the creation of a short film [Tits Up](#) about experience and challenge of a Lobular diagnosis.

National Lottery Community Fund's *Awards for All* programme provided our first grant of over £9,000 towards the development of information resources and the delivery of a series of supportive workshops for people diagnosed with Lobular.



On the 796m summit of Mam na Gualainn, the final day of *Walking our Mammaries* (Left to right) Joy Martin, Danni Buck, Kirstin Spencer, Elaine Nangle, Josie Lloyd, Helen Coulthard, Emma Amos and Claire Turner

⁵ After Breast Cancer Diagnosis <https://www.abcdiagnosis.co.uk>

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

STAKEHOLDER CONSULTATION

In 2023 we conducted our first Annual Survey to measure our impact during 2022 and to ensure that our activities meet the needs and tackle the concerns of Lobular patients. 143 people completed the survey, all, apart from 1 person, had had a Lobular diagnosis.

- 87% of respondents state our work has **increased their knowledge of Lobular**.
- 66% of respondents state our work has **reduced their isolation and fear about a Lobular diagnosis**.
- 59% of respondents state our work has **helped build their confidence** in speaking with their medical team about Lobular.

We are delighted to see that we are impacting on people's lives but recognise that we have many improvements to make.

Priorities for respondents included:

- changing treatment guidelines;
- working globally to drive forward research and engage patient advocates in research;
- continuing to understand and support the needs of Lobular patients;
- develop Lobular specific information and sharing patient stories;
- increasing patients' understanding of Lobular Breast Cancer.

The Survey is being used to assist with our future strategic planning.

FINANCIAL REVIEW

As a volunteer run charity, we currently have few overheads.

Our annual budgets are approved and monitored by the Board at each meeting. Any variances from the proposed budget are highlighted and discussed at the meetings.

In the opinions of the Trustees, the Charitable Company's assets are sufficient to fulfil the obligations of the Charity.

RESERVES POLICY

During 2022, the Board has maintained a zero Reserves Policy due to very limited fixed operational costs within LBCUK (especially no staff costs). Additionally, 2022 accounts would provide us with a clearer picture operational overheads required as the first full year of activities.

A new Reserves Policy is now in place based on the 2022 accounts figures. We will maintain our reserves at a level which is at equivalent to between three - six months' operational expenditure with a target of £4,000. At the balance sheet date the charity held total funds of £22,815 including £14,551 in restricted funds leaving £8,264 in free reserves.

Due to the success of funding during 2022, we are able to plan for the next three years of strategic delivery focusing on the feedback from our Annual Survey.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

REVIEW OF RISKS

The Trustees have considered the major risks facing the charity and have put in place appropriate policies and procedures to mitigate them.

The primary risk to the charity is the growing demand for our services and the lack of personnel resource to meet this demand. A new Trustee recruitment process has been developed for 2023 to be followed by operational volunteer recruitment.

FUTURE PLANS

Our future plans focus on building activity to achieve the five key strategic aims of our charity.

AIM 1: INFORMATION & EDUCATION: we advance education and understanding of lobular breast cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

AIM 2: POLICY & TREATMENT GUIDELINES: we will work with partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries.

AIM 3: RESEARCH: we will work with patients, clinicians and health professionals to ensure that research and trials conducted for lobular breast cancer meet the needs of patients, and we will raise funds for research projects.

AIM 4: SUPPORT: we provide routes to appropriate support and connection for patients, reducing the isolation and fear of a lobular breast cancer diagnosis.

AIM 5: OUR IMPACT: we continue to build LBCUK as an effective, professional and sustainable independent charity, increasing our impact.

A key focus for 2023 and beyond is the development of a campaign to establish clinical recognition of Lobular Breast Cancer/Invasive Lobular Carcinoma (ILC) as a distinct disease across the four countries of the UK. It is a disease that requires its own specific targeted treatments and treatment guidelines.

We will continue to build stronger collaborative relationships across the UK and internationally with other lobular specific and breast cancer charities.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

STRUCTURE GOVERNANCE & MANAGEMENT

GOVERNING DOCUMENT

The Charity is a Charitable Incorporated Organisation and is governed by its Foundation CIO Constitution. It is registered as a CIO with the Charity Commission for England & Wales.

TRUSTEE INDUCTION, RECRUITMENT & TRAINING

The Trustees are collectively known as the Board.

Trustees are appointed by invitation from the existing Trustees and through an open recruitment process, following a majority vote of the Trustees of the Charity.

Invited potential Trustees are requested to either provide a CV and covering letter/three minute short film for consideration by the Board or to complete a formal application process for open recruitment. All Trustees are interviewed by a panel of at least two Trustees and a recommendation is made to the Board if they are determined to be suitable to be invited as a Trustee.

New Trustees are provided with a copy of the Charity Commission's leaflet for new Trustees, 'The Essential Trustee: what you need to know, what you need to do' (CC3), a copy of our Constitution, a copy of the Charity Governance Code, recent Board minutes and latest Annual Report and Accounts. They also receive a briefing and annual reviews with the current Chair.

ORGANISATION

The Charity is governed by the Board and managed by the charity's Trustees and four voluntary Founders. The Trustees who have acted during the year are listed above. Four of the listed Trustees are also Founders of the charity.

Trustees meet approximately 4 - 5 times a year to discuss and agree on matters of charity governance, policy and strategy. Further ad hoc meetings are organised as required to address specific issues. Trustees develop strategies to increase charity awareness, widen reach across our stakeholders and build the sustainability of this new and growing organisation.

These meetings also include budget reports and cash flow. Any changes in strategy are discussed, amended and when agreed, adopted as written charity policy by Trustees.

Where risks are identified, steps are taken to mitigate these risks, including reference to how the charity has met its charitable aims in the advancement of education, training, support, research and advocacy. Any actions taken are then reported on and reviewed at subsequent meetings.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Trustees Report
FOR THE YEAR ENDED 31 DECEMBER 2022

The implementation of policies and strategies is delivered operationally by the five Trustees and the four volunteer Founder Members. To ensure that our activities are evidence based and reflect the latest scientific knowledge about lobular breast cancer. We have a Scientific and Medical Advisory Group involving six respected clinicians and researchers in the field of Lobular Breast Cancer.

We have no premises and are based across the UK.

All Trustees and relevant volunteers are DBS checked and participate in relevant training programmes.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Responsibilities of the Trustees
FOR THE YEAR ENDED 31 DECEMBER 2022

RESPONSIBILITIES OF THE TRUSTEES

Under charity law, the Trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the CIO constitution. It is also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Signed by order of the Trustees



C Turner
Chair of Trustees
October 2022

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Independent Examiner's Report to the trustees
FOR THE YEAR ENDED 31 DECEMBER 2022

I report to the Charity trustees on my examination of the accounts of the Charity for the year ended 31 December 2022 which are set out on pages 9 to 16.

Respective responsibilities of trustees and examiner

As the Charity's trustees of Lobular Breast Cancer UK (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Lobular Breast Cancer UK's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- accounting records were not kept in respect of Lobular Breast Cancer UK as required by section 130 of the 2006 Act; or
- the accounts do not accord with those records; or
- the accounts do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Helen Binns FCA
Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Date: 31 October 2023

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Statement of Financial Activities
(Including Income and Expenditure Account and Statement of Total
Recognised Gains and Losses)
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	Unrestricted funds £	Restricted funds £	Total 31 December 2022 £
Income and Endowments from:				
Donations and legacies	3	19,951	9,952	29,903
Total income		19,951	9,952	29,903
Expenditure on:				
Raising funds		(4,080)	-	(4,080)
Charitable activities	5	(3,668)	(1,688)	(5,356)
Total expenditure		(7,748)	(1,688)	(9,436)
Net income		12,203	8,264	20,467
Net movement in funds		12,203	8,264	20,467
Reconciliation of funds				
Total funds brought forward		2,348	-	2,348
Total funds carried forward	11	14,551	8,264	22,815

	Note	Unrestricted funds £	Total 31 December 2021 £
Income and Endowments from:			
Donations and legacies	3	2,576	2,576
Other trading activities	4	2,422	2,422
Total income		4,998	4,998
Expenditure on:			
Raising funds		(1,404)	(1,404)
Charitable activities	5	(1,246)	(1,246)
Total expenditure		(2,650)	(2,650)
Net income		2,348	2,348
Reconciliation of funds			
Total funds carried forward	11	2,348	2,348

All of the Charity's activities derive from continuing operations during the above two periods.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
(Registration number: CE023524)
Balance Sheet
AS AT 31 DECEMBER 2022

	Note	31 December 2022 £	31 December 2021 £
Current assets			
Cash at bank and in hand		24,375	2,348
Creditors: Amounts falling due within one year	10	(1,560)	-
Net assets		22,815	2,348
Funds of the Charity:			
Restricted funds		8,264	-
Unrestricted income funds			
Unrestricted funds		14,551	2,348
Total funds	11	22,815	2,348

The financial statements on pages 9 to 16 were approved by the trustees, and authorised for issue on 26 October 2023 and signed on their behalf by:



Claire L Turner
Trustee

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Charity status

The Charity is a Charitable Incorporated Organisation, incorporated in England and Wales.

The address of its registered office is:

83 Ducie Street
Manchester
M1 2JQ

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") the Charities Act 2011, and Charities (Accounts and Reports) Regulations 2008, as well as the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" 2019.

Basis of preparation

Lobular Breast Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost.

Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the Charity.

Exemption from preparing a cash flow statement

The Charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the Charity before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that these conditions will be fulfilled in the reporting period.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

Grants receivable

Grants are recognised when the Charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the Charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Grants

Grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the Charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charitable incorporated organisation becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable incorporated organisation after deducting all of its liabilities.

3 Income from donations and legacies

	Unrestricted funds		Total 31 December 2022 £	Total 22 September 2020 to 31 December 2021 £
	General £	Restricted funds £		
Donations and legacies;				
Donations from individuals	17,268	-	17,268	2,349
Gift aid reclaimed	2,683	-	2,683	227
Grants	-	9,952	9,952	-
	<u>19,951</u>	<u>9,952</u>	<u>29,903</u>	<u>2,576</u>

4 Income from other trading activities

	Total 31 December 2022 £	Total 22 September 2020 to 31 December 2021 £
Events income;		
Other events income	-	2,155
Sponsorship income	-	267
	<u>-</u>	<u>2,422</u>

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

5 Expenditure on charitable activities

		Unrestricted funds		Total	Total
	Note	General	Restricted	31 December	22 September
		£	funds	2022	2020 to 31
			£	£	December
					2021
					£
Allocated support costs	6	-	1,688	1,688	-
Governance costs	6	1,388	-	1,388	1,246
		2,280	-	2,280	-
		<u>3,668</u>	<u>1,688</u>	<u>5,356</u>	<u>1,246</u>

6 Governance Costs

	Total	Total
	31 December	22 September
	2022	2020 to 31
	£	December
		2021
		£
Independent examiner fees:		
Examination of the financial statements	780	-
Other fees paid to examiners	1,500	-
	<u>2,280</u>	<u>-</u>

7 Trustees

No trustees, nor any persons connected with them, have received any remuneration from the Charity during the year.

One trustee was reimbursed expenses totalling £76 (2021: £Nil). No trustees received any other benefits from the charity during the year.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

8 Independent examiner's remuneration

	Year ended 31 December 2022 £
Examination of the financial statements	780
Other fees to examiners	
Accounts preparation	780
Prior year accounts preparation	720
	1,500

9 Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

10 Creditors: amounts falling due within one year

	31 December 2022 £
Accruals	1,560

11 Funds

	Balance at 1 January 2022 £	Incoming resources £	Resources expended £	Balance at 31 December 2022 £
Unrestricted funds				
General	2,348	19,951	(7,748)	14,551
Restricted funds	-	9,952	(1,688)	8,264
Total funds	2,348	29,903	(9,436)	22,815

	Incoming resources £	Resources expended £	Balance at 31 December 2021 £
Unrestricted funds			
General	4,998	(2,650)	2,348

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2022

12 Analysis of net assets between funds

	Unrestricted funds		
	General	Restricted	Total funds
	£	funds	£
		£	
Current assets	16,111	8,264	24,375
Current liabilities	(1,560)	-	(1,560)
Total net assets	14,551	8,264	22,815

LOBULAR BREAST CANCER UK

England & Wales - Charity number 1191402

Accounts

Charitable incorporated organisation registration number: CE023524

Charitable incorporated organisation registration number: 1191402

Lobular Breast Cancer UK

(A charitable incorporated organisation)

Annual Report and Financial Statements

for the period from 22 September 2020 to 31 December 2021



*Working together we
can all live well*

Lobular Breast Cancer UK

Contents

Reference and Administrative Details	1
Chair's Statement	2
Trustees' Report	3 to 8
Statement of Trustees' Responsibilities	9
Accountants' Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Financial Statements	13 to 17

Lobular Breast Cancer UK

Reference and Administrative Details

Trustees	Claire L Turner, Chair Elaine Nangle Emma Amos Danielle Buck Dr Helen L Coulthard
Registered and Principal Office	83 Ducie Street Manchester M1 2JQ The charitable incorporated organisation is incorporated in England and Wales.
Charitable incorporated organisation registration Number	CE023524
Charitable incorporated organisation Registration Number	1191402
Bankers	The Co-operative Bank PO Box 250 Def House Southway Skelmersdale WN8 6WT
Accountants	Beever and Struthers St George's House 215-219 Chester Road Manchester M15 4JE

Lobular Breast Cancer UK

Chair's Statement

"Never doubt that a small group of thoughtful committed individuals can change the world."

Margaret Mead

Having a breast cancer diagnosis is a traumatic experience. Being given a diagnosis and then being told it's a disease that you've never even heard of, only compounds the fear and sense of isolation. This is the experience of most people on being told that they have lobular breast cancer: the second most prevalent subtype of this disease.

Despite making up around 15% of all breast cancers, there are no targeted treatments for lobular despite research demonstrating that it behaves and responds to treatments in a unique way.

Covid-19 has also had a devastating effect on cancer treatment since 2020 with increased waiting times, delays in diagnosis and treatments being postponed or stopping completely.

Whilst I would never advise anyone to set up a charity in the middle of a global pandemic, it highlighted the importance of patient focused organisations in driving forward our needs and ensuring that we are at the heart of new knowledge, innovations and clinical change.

I am really proud of what we have achieved in our first year as a small group of volunteers. We are already seeing impacts from the work we have begun.

I want to personally thank our Founder Members & first Trustees Emma Amos, Danni Buck, Helen Coulthard, Darlaine Honey, Lorna McHattie, Kirstin Spencer and Ruth Warden for their vision, energy and commitment in launching our Charity. We are all living with a lobular breast cancer diagnosis.

Our Board joins me in thanking our first Patron Josie Lloyd, who has had her own lobular diagnosis; our Scientific and Medical Advisory Group; our families, friends, supporters, funders and partners especially our international partners Lobular Breast Cancer Alliance, Lobular Ireland and the European Lobular Breast Cancer Consortium.

We look forward to 2022 with renewed vigour and a commitment to unlocking the primary challenges presented by this distinct disease that is lobular breast cancer.

With warm wishes

Claire Turner

Chair

Lobular Breast Cancer UK

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the period ended 31 December 2021.

Trustees

Claire L Turner, Chair (appointed 22 September 2020)

Elaine Nangle (appointed 1 January 2022)

Emma Amos (appointed 15 August 2021)

Dannielle Buck (appointed 22 September 2020)

Dr Helen L Coulthard (appointed 22 September 2020)

Lorna McHattie (appointed 22 September 2020 and resigned 31 December 2021)

Objectives and activities

Objects and aims

The object of the CIO is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around lobular breast cancer.

Review of Activities

We lead with our purpose “Working together, we can all live well” and our primary value “The patient is always first”

Launching a new charity in the middle of a global pandemic was no mean feat but it demonstrated our resilience, professionalism and commitment to making changes in the lives of everyone with a lobular breast cancer diagnosis.

The restrictions of the pandemic prevented us from providing activity in a face-to-face capacity, and actually accentuated the isolation that many people feel from a lobular breast cancer diagnosis.

We had to rethink the initial plans for our first year identifying what we could do digitally and remotely that enabled us to drive forward our aims and provide public benefit.

In October 2021, published author Josie Lloyd joined us as our first Patron, bringing her own lived experience of a lobular diagnosis to the charity.

Stakeholder Consultation

We held a series of online consultation workshops with people who have had a lobular breast cancer diagnosis. This was to ensure that our plans were in line with the needs of a broad range of people and not simply the initial founder members.

This consultation has been fed into our plans for the charity.

Lobular Breast Cancer UK

Trustees' Report

Objectives, strategies and activities

Information

Our public launch was delayed as we prepared for a soft online launch in September 2021. We worked towards the launch of our website that provided relevant, informative, evidence based information for inclusion on the website.

We developed a very clear brand that established LBCUK as a distinct disease and separated us from the primarily "pink-focused" campaigning of most breast cancer charities and campaigns. Lobular is a distinct disease that needs separate research and treatment protocols, and we wanted our brand to reflect this.



Our website and social media launched on 30 September 2021 providing information and downloadable resources for anyone with a lobular diagnosis. Within the first three months, we reached over 100,000 people across our social media channels.

Hugely popular was a short video we created with BBC News' Jane Hill, who has had her own lobular breast cancer diagnosis speaking with Consultant Radiologist Soujanya Gadde.

To ensure that our information is evidence based we work with our Scientific & Medical Advisory Group who support our work and check all our communications for accuracy. A huge thank you to Professor Val Brunton, Dr Soujanya Gadde Consultant Radiologist, Senior Breast Care Nurse Lottie Milns, Dr Sankari Najaran, Dr Alicia Okines, and Professor Elinor Sawyer for their support.

Sadly, this year, Dr Andy Sims, who was the first scientist to support us with the development of LBCUK and the first member of our Advisory Group, died of melanoma in May 2021. Andy led a research team at the Institute of Cancer and Genetics at the University of Edinburgh and was an outstanding scientist. His death is a huge loss. His legacy will endure through his research achievements and through all of us who have benefited from knowing him. He will be remembered fondly, and his great smile will always be with us.

Research

Internationally we work with our international partner organisations, clinicians and researchers to collaborate on lobular research. Our Chair is UK Patient Advocate with the European Lobular Breast Cancer Consortium (ELBCC), sits on the Patient Advocacy group and is part of a Global Advocacy group that work together.

Lobular Breast Cancer UK

Trustees' Report

In October 2021, working with De Montfort University, we launched a Delphi study Setting Priorities for lobular breast cancer research: a patient-led consensus study led by Dr Helen Coulthard and Dr Lorna McHattie to help lead out work in the UK. The study will be published in 2022.

With imaging being a huge issue for lobular patients, De Montfort University MA student Victoria Rake, began a study to understand the experience of having a cancer that has been missed on mammogram: Missed Cancers: Lobular Breast Cancer that has been missed on screening. The findings will be published in 2022.

We lead with our purpose “Working together, we can all live well” and our primary value “The patient is always first”

Launching a new charity in the middle of a global pandemic was no mean feat but it demonstrated our resilience, professionalism and commitment to making changes in the lives of everyone with a lobular breast cancer diagnosis.

The restrictions of the pandemic prevented us from providing activity in a face-to-face capacity, and actually accentuated the isolation that many people feel from a lobular breast cancer diagnosis.

We had to rethink the initial plans for our first year identifying what we could do digitally and remotely that enabled us to drive forward our aims and provide public benefit.

In October 2021, published author Josie Lloyd joined us as our first Patron, bringing her own lived experience of a lobular diagnosis to the charity.

Fundraising disclosures

We began planning the delivery of our first pilot fundraising event Walking our Mammaries, a mountain challenge tackling peaks named after breasts. The challenge will take place in May 2022 in Scotland. In October 2021, 8 women took part in the first training weekend for the challenge in the Peak District.

We have received donations and in-kind support from companies Boom Solutions, Eden Search, Joy of Adventure, Large Outdoors and individual donations from family and friend supporters in helping us to fund the first year of our charity.

Public benefit

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial review

As a volunteer run charity we currently have no overheads.

Our annual budgets are approved and monitored by the Board at each quarterly meeting. Any variances from the proposed budget are highlighted and discussed at the meetings.

In the opinions of the Trustees, the Charitable Company's assets are sufficient to fulfil the obligations of the Charity.

Lobular Breast Cancer UK

Trustees' Report

Policy on reserves

For the first year, the Board has agreed to have zero reserves due to there being very limited fixed operational costs within LBCUK (especially no staff costs) and no picture of the actual overheads and income streams that we will be accessing as a new charity.

In the long term, the trustees propose to maintain the charity's reserves at a level which is at least equivalent to three/six months' operational expenditure. This figure will be set after production of our first charity accounts..

Plans for future periods

Aims and key objectives for future periods

Our future plans focus on building activity to achieve the four key aims of our charity:

AIM 1: INFORMATION & EDUCATION: we advance education and understanding of lobular breast cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

AIM 2: POLICY & TREATMENT GUIDELINES: we will work with partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries.

AIM 3: RESEARCH: we will work with patients, clinicians and health professionals to ensure that research and trials conducted for lobular breast cancer meet the needs of patients, and we will raise funds for research projects.

AIM 4: SUPPORT: we provide routes to appropriate support and connection for patients, reducing the isolation and fear of a lobular breast cancer diagnosis.

A key focus for 2022 is to start providing activity that brings together people who have had a lobular diagnosis helping to reduce their isolation and provide information in a safe and supportive environment.

We want to build stronger collaborative relationships across the UK and internationally with other lobular specific and breast cancer charities. In June 2022, we will be attending the annual International ILC Symposium to build knowledge about LBCUK, strengthen existing and build new relationships, and to be at the forefront of research into this distinct disease.

Structure, governance and management

Nature of governing document

The Charity is a Charitable Incorporated Organisation and is governed by its Foundation CIO Constitution. It is registered as a CIO with the Charity Commission for England & Wales.

Lobular Breast Cancer UK

Trustees' Report

Recruitment and appointment of trustees

The Trustees are collectively known as the Board.

Trustees are appointed by invitation from the existing Trustees and through an open recruitment process, following a majority vote of the Trustees of the Charity.

Invited potential Trustees are requested to either provide a CV and covering letter for consideration by the Board or to complete a formal application process for open recruitment. All Trustees are interviewed by a panel of three Trustees and a recommendation is made to the Board if they are determined to be suitable to be invited as a Trustee.

Induction and training of trustees

New Trustees are provided with a copy of the Charity Commission's leaflet for new Trustees, 'The Essential Trustee: what you need to know, what you need to do' (CC3), copy of our Constitution, a copy of the Charity Governance Code, recent Board minutes and Annual Report and Accounts. They also receive a briefing with the current Chair.

Organisational structure

The Charity is governed by the Board and managed by the charity's Trustees and four voluntary Founder Members. The Trustees who have acted during the year are listed above.

Trustees meet together approximately 4 - 5 times a year to discuss and agree on all matters of charity governance, policy and strategy. Further ad hoc meetings are organised as required to address specific issues. Trustees develop strategies to increase charity awareness, widen reach across our stakeholders and build the sustainability of this new and growing organisation.

These meetings also include budget reports and cash flow. Any changes in strategy are discussed, amended and when agreed, adopted as written charity policy by Trustees.

Where risks are identified, steps are taken to mitigate these risks, including reference to how the charity has met its charitable aims in the advancement of education, training, support, research and advocacy. Any actions taken are then reported on and reviewed at subsequent meetings.

The implementation of policies and strategies is delivered operationally by the five Trustees and the four volunteer Founder Members. To ensure that all of our activities are evidence based and reflect the latest scientific knowledge about lobular breast cancer, we have a Scientific and Medical Advisory Group involving five respected clinicians and researchers in the field of lobular breast cancer.

We have no premises and are based across the UK.

All Trustees and relevant volunteers are DBS checked and participate in relevant training programmes.

Lobular Breast Cancer UK

Trustees' Report

Major risks and management of those risks

Review of Risks

The Trustees have considered the major risks facing the charity and have put in place appropriate policies and procedures to mitigate them.

COVID 19 remains an on-going concern, especially when working with people who may be vulnerable, and we continue to follow government guidelines in this area.

The annual report was approved by the trustees of the charitable incorporated organisation on 31 October 2022 and signed on its behalf by:

.....
Claire L Turner
Trustee

Lobular Breast Cancer UK

Statement of Trustees' Responsibilities

Under charity law, the charity trustees are responsible for preparing the trustee's annual report and financial statements for each financial year in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the CIO constitution. It is also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charitable incorporated organisation on 31 October 2022 and signed on its behalf by:

.....
Claire L Turner
Trustee

**Chartered Accountants' Report to the Trustees on the Preparation of the Unaudited
Statutory Accounts of
Lobular Breast Cancer UK
for the Period Ended 31 December 2021**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Lobular Breast Cancer UK for the period ended 31 December 2021 as set out on pages 11 to 17 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at <http://www.icaew.com/en/members/regulations-standards-and-guidance/>].

This report is made solely to the Board of Directors of Lobular Breast Cancer UK, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Lobular Breast Cancer UK and state those matters that we have agreed to state to the Board of Directors of Lobular Breast Cancer UK, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Lobular Breast Cancer UK and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Lobular Breast Cancer UK has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and results of Lobular Breast Cancer UK. You consider that Lobular Breast Cancer UK is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the accounts of Lobular Breast Cancer UK. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

.....
Beever and Struthers
St George's House
215-219 Chester Road
Manchester
M15 4JE
31 October 2022

Lobular Breast Cancer UK

Statement of Financial Activities for the Period from 22 September 2020 to 31 December 2021 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2021 £
Income and Endowments from:			
Donations and legacies	3	2,576	2,576
Other trading activities	4	<u>2,422</u>	<u>2,422</u>
Total income		<u>4,998</u>	<u>4,998</u>
Expenditure on:			
Raising funds	5	(1,404)	(1,404)
Charitable activities	6	<u>(1,246)</u>	<u>(1,246)</u>
Total expenditure		<u>(2,650)</u>	<u>(2,650)</u>
Net income		<u>2,348</u>	<u>2,348</u>
Net movement in funds		<u>2,348</u>	<u>2,348</u>
Reconciliation of funds			
Total funds carried forward	10	<u><u>2,348</u></u>	<u><u>2,348</u></u>

All of the charitable incorporated organisation's activities derive from continuing operations during the above period.

The notes on pages 13 to 17 form an integral part of these financial statements.

Lobular Breast Cancer UK
(Registration number: CE023524)
Balance Sheet as at 31 December 2021

	Note	2021 £
Current assets		
Cash at bank and in hand	9	<u>2,348</u>
Funds of the charitable incorporated organisation:		
Unrestricted income funds		
Unrestricted funds		<u>2,348</u>
Total funds	10	<u>2,348</u>

The financial statements on pages 11 to 17 were approved by the trustees, and authorised for issue on 31 October 2022 and signed on their behalf by:

.....
Claire L Turner
Trustee

The notes on pages 13 to 17 form an integral part of these financial statements.

Lobular Breast Cancer UK

Notes to the Financial Statements for the Period from 22 September 2020 to 31 December 2021

1 Charitable incorporated organisation status

The charitable incorporated organisation is limited by guarantee, incorporated in England and Wales.

The address of its registered office is:
83 Ducie Street
Manchester
M1 2JQ

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") the Charities Act 2011, and Charities (Accounts and Reports) Regulations 2008, as well as the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" 2019.

Basis of preparation

Lobular Breast Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charitable incorporated organisation's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charitable incorporated organisation.

Exemption from preparing a cash flow statement

The charitable incorporated organisation opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the charitable incorporated organisation has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Lobular Breast Cancer UK

Notes to the Financial Statements for the Period from 22 September 2020 to 31 December 2021

Donations and legacies

Donations are recognised when the charitable incorporated organisation has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charitable incorporated organisation before the charitable incorporated organisation is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charitable incorporated organisation and it is probable that these conditions will be fulfilled in the reporting period.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charitable incorporated organisation in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charitable incorporated organisation.

Lobular Breast Cancer UK

Notes to the Financial Statements for the Period from 22 September 2020 to 31 December 2021

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charitable incorporated organisation becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable incorporated organisation after deducting all of its liabilities.

3 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
Donations from individuals	2,349	2,349
Gift aid reclaimed	227	227
Total for period ended 31 December 2021	2,576	2,576

4 Income from other trading activities

	Unrestricted funds General £	Total funds £
Events income;		
Other events income	2,155	2,155
Sponsorship income	267	267
Total for period ended 31 December 2021	2,422	2,422

5 Expenditure on raising funds

a) Costs of trading activities

	Note	Unrestricted funds General £	Total funds £
Events and conferences		1,404	1,404
Total for period ended 31 December 2021		1,404	1,404

Lobular Breast Cancer UK

Notes to the Financial Statements for the Period from 22 September 2020 to 31 December 2021

		Unrestricted funds General £	Total costs £
6 Expenditure on charitable activities			
	Note		
Allocated support costs		1,246	1,246

7 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charitable incorporated organisation during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

8 Taxation

The charitable incorporated organisation is a registered charity and is thus exempted from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the year.

9 Cash and cash equivalents

	2021 £
Cash at bank	2,348

10 Funds

	Incoming resources £	Resources expended £	Balance at 31 December 2021 £
Unrestricted funds			
General	4,998	(2,650)	2,348

11 Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 December 2021 £
Current assets	2,348	2,348

Lobular Breast Cancer UK

Notes to the Financial Statements for the Period from 22 September 2020 to 31 December 2021

12 Related party transactions

There were no related party transactions in the period.